-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In the Phase III OlympiAD trial, olaparib significantly prolonged the progression-free progression of human epidermal growth factor 2 (HER2) negative metastatic breast cancer (mBC) patients with BRCA germline mutation (gBRCAm) compared with the chemotherapy determined by the doctor Lifetime (PFS)
Breast cancer
The Phase IIIb LUCY trial aims to evaluate the clinical effectiveness of olapa in similar patients in an environment that reflects clinical practice
Evaluate the clinical effectiveness of olapa in similar patients in an environment that reflects clinical practice
The LUCY trial is an open-label, single-arm clinical trial that recruits BRCAm and HER2-negative mBC patients who have previously received taxane and/or anthracycline therapy under (new) adjuvant/metastatic conditions, and targeted There is no more chemotherapy for mBC than second-line chemotherapy
PFS of the entire queue
PFS of the entire queueOf the 563 patients screened , 252 patients with gBRCAm were recruited and received at least one dose of olaparib
Screening 252 patients with gBRCAm The median investigator-assessed PFS was 8.
The most common adverse events requiring emergency treatment
The most common adverse events requiring emergency treatmentThe most common adverse events requiring emergency treatment (TEAE: >20% of patients) are nausea, anemia, weakness, vomiting, and fatigue
In summary, in clinical practice, olapa has good efficacy in gBRCAm and HER2-negative mBC patients, and its safety is consistent with previous research reports
In clinical practice, olapa has good efficacy in gBRCAm and HER2-negative mBC patients, and its safety is consistent with previous research reports.
Original source:
Gelmon Karen A,Fasching Peter A,Couch Fergus J et al.
Clinical effectiveness of olaparib monotherapy in germline BRCA -mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis
in this message
